Fisher & Paykel Healthcare settles ResMed IP battle
CEO Lewis Gradon says why.
Fisher & Paykel Healthcare and NYSE-listed ResMed have settled an intellectual property battle they have been waging since August 2016.
The market reacted optimistically to the news, with Fisher & Paykel's share price rising 6.5% on yesterday's closing price to $14.25 in early trading.
In a
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Smartphone Only Annual Subscription
NZ$249.00 / yearly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Subscription
NZ$29.95 / monthly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
